Literature DB >> 19961830

Molecular and phenotypic reassessment of an infrequently used mouse model for spinal muscular atrophy.

Rocky G Gogliotti1, Suzan M Hammond, Cathleen Lutz, Christine J Didonato.   

Abstract

Proximal spinal muscular atrophy (SMA) results from loss of the survival motor neuron 1 (SMN1) gene, with retention of its nearly identical homolog, SMN2. There is a direct correlation between disease severity and SMN2 copy number. Mice do not have a Smn2 gene, and thus cannot naturally replicate the disorder. However, two murine models of SMA have been generated using SMN2-BAC transgenic mice bred onto a mutant Smn background. In these instances mice die shortly after birth, have variable phenotypes within the same litter, or completely correct the SMA phenotype. Both models have been imported to The Jackson Laboratory for distribution to the research community. To ensure that similar results are obtained after importation to The Jackson Laboratory to what was originally reported in the literature, we have begun a molecular and phenotypic evaluation of these mouse models. Here we report our findings for the SMA mouse model that has been deposited by the Li group from Taiwan. These mice, JAX stock number TJL-005058, are homozygous for the SMN2 transgene, Tg(SMN2)2Hung, and a targeted Smn allele that lacks exon 7, Smn1(tm1Hung). Our findings are consistent with those reported originally for this line and clarify some of the original data. In addition, we have cloned and mapped the integration site for Tg(SMN2)2Hung to Chromosome 4, and provide a simple genotyping assay that is specific to the junction fragment. Finally, based upon the survival data from our genetic crosses, we suggest that this underused SMA model may be a useful compliment or alternative to the more commonly used "delta7" SMA mouse. We provide breeding schemes in which two genotypes of mice can be generated so that 50% of the litter will be SMA-like pups while 50% will be controls. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19961830      PMCID: PMC2814331          DOI: 10.1016/j.bbrc.2009.11.090

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos.

Authors:  B Schrank; R Götz; J M Gunnersen; J M Ure; K V Toyka; A G Smith; M Sendtner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  The survival motor neuron protein in spinal muscular atrophy.

Authors:  D D Coovert; T T Le; P E McAndrew; J Strasswimmer; T O Crawford; J R Mendell; S E Coulson; E J Androphy; T W Prior; A H Burghes
Journal:  Hum Mol Genet       Date:  1997-08       Impact factor: 6.150

Review 3.  The neurobiology of childhood spinal muscular atrophy.

Authors:  T O Crawford; C A Pardo
Journal:  Neurobiol Dis       Date:  1996-04       Impact factor: 5.996

4.  Nuclear targeting defect of SMN lacking the C-terminus in a mouse model of spinal muscular atrophy.

Authors:  T Frugier; F D Tiziano; C Cifuentes-Diaz; P Miniou; N Roblot; A Dierich; M Le Meur; J Melki
Journal:  Hum Mol Genet       Date:  2000-03-22       Impact factor: 6.150

5.  A mouse model for spinal muscular atrophy.

Authors:  H M Hsieh-Li; J G Chang; Y J Jong; M H Wu; N M Wang; C H Tsai; H Li
Journal:  Nat Genet       Date:  2000-01       Impact factor: 38.330

6.  A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy.

Authors:  C L Lorson; E Hahnen; E J Androphy; B Wirth
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

7.  Cloning, characterization, and copy number of the murine survival motor neuron gene: homolog of the spinal muscular atrophy-determining gene.

Authors:  C J DiDonato; X N Chen; D Noya; J R Korenberg; J H Nadeau; L R Simard
Journal:  Genome Res       Date:  1997-04       Impact factor: 9.043

8.  Identification and characterization of a spinal muscular atrophy-determining gene.

Authors:  S Lefebvre; L Bürglen; S Reboullet; O Clermont; P Burlet; L Viollet; B Benichou; C Cruaud; P Millasseau; M Zeviani
Journal:  Cell       Date:  1995-01-13       Impact factor: 41.582

9.  Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo.

Authors:  Christopher R Heier; Christine J DiDonato
Journal:  Hum Mol Genet       Date:  2009-01-15       Impact factor: 6.150

10.  A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy.

Authors:  Umrao R Monani; Matthew T Pastore; Tatiana O Gavrilina; Sibylle Jablonka; Thanh T Le; Catia Andreassi; Jennifer M DiCocco; Christian Lorson; Elliot J Androphy; Michael Sendtner; Michael Podell; Arthur H M Burghes
Journal:  J Cell Biol       Date:  2003-01-06       Impact factor: 10.539

View more
  28 in total

Review 1.  Spinal muscular atrophy: an update on therapeutic progress.

Authors:  Joonbae Seo; Matthew D Howell; Natalia N Singh; Ravindra N Singh
Journal:  Biochim Biophys Acta       Date:  2013-08-27

2.  Interaction between alpha-COP and SMN ameliorates disease phenotype in a mouse model of spinal muscular atrophy.

Authors:  Sara K Custer; Jacob W Astroski; Hong Xia Li; Elliot J Androphy
Journal:  Biochem Biophys Res Commun       Date:  2019-05-03       Impact factor: 3.575

3.  Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.

Authors:  Yimin Hua; Kentaro Sahashi; Gene Hung; Frank Rigo; Marco A Passini; C Frank Bennett; Adrian R Krainer
Journal:  Genes Dev       Date:  2010-07-12       Impact factor: 11.361

4.  Autophagy dysregulation in cell culture and animals models of spinal muscular atrophy.

Authors:  Sara K Custer; Elliot J Androphy
Journal:  Mol Cell Neurosci       Date:  2014-06-28       Impact factor: 4.314

Review 5.  Assays for the identification and prioritization of drug candidates for spinal muscular atrophy.

Authors:  Jonathan J Cherry; Dione T Kobayashi; Maureen M Lynes; Nikolai N Naryshkin; Francesco Danilo Tiziano; Phillip G Zaworski; Lee L Rubin; Jill Jarecki
Journal:  Assay Drug Dev Technol       Date:  2014-08       Impact factor: 1.738

Review 6.  In vitro neurogenesis: development and functional implications of iPSC technology.

Authors:  Claudia Compagnucci; Monica Nizzardo; Stefania Corti; Ginevra Zanni; Enrico Bertini
Journal:  Cell Mol Life Sci       Date:  2013-11-20       Impact factor: 9.261

7.  Characterization of a large human transgene following invasin-mediated delivery in a bacterial artificial chromosome.

Authors:  Austin E Gillen; Catherine A Lucas; Pei Ling Haussecker; Steven T Kosak; Ann Harris
Journal:  Chromosoma       Date:  2013-06-09       Impact factor: 4.316

8.  Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy.

Authors:  Suzan M Hammond; Gareth Hazell; Fazel Shabanpoor; Amer F Saleh; Melissa Bowerman; James N Sleigh; Katharina E Meijboom; Haiyan Zhou; Francesco Muntoni; Kevin Talbot; Michael J Gait; Matthew J A Wood
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-12       Impact factor: 11.205

9.  DNA Damage Response and DNA Repair in Skeletal Myocytes From a Mouse Model of Spinal Muscular Atrophy.

Authors:  Saniya Fayzullina; Lee J Martin
Journal:  J Neuropathol Exp Neurol       Date:  2016-07-24       Impact factor: 3.685

10.  The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models.

Authors:  Rocky G Gogliotti; Herminio Cardona; Jasbir Singh; Sophie Bail; Carina Emery; Nancy Kuntz; Michael Jorgensen; Madel Durens; Bing Xia; Courtenay Barlow; Christopher R Heier; Heather L Plasterer; Vincent Jacques; Megerditch Kiledjian; Jill Jarecki; James Rusche; Christine J DiDonato
Journal:  Hum Mol Genet       Date:  2013-06-04       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.